Metabolic syndrome in severe mental disorders
Affiliations
Affiliations
- Department of Psychiatry, Psychological Medicine Hospital, Safat, Kuwait. judeohaeri@hotmail.com
Abstract
The concept of metabolic syndrome in psychiatry provides a united front for confronting a series of metabolic changes that are predictive of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), which are highly prevalent in severe mental disorders (SMDs), such as schizophrenia, bipolar disorders, and severe depression. This review attempts to answer the following questions: (1) Is there evidence of significantly increased risk of metabolic syndrome in SMDs? (2) How is this evidence explained by stress theory and functional polymorphism? (3) What role can psychopharmacology and psychosocial therapies play in minimizing the problem? We have done a historical review using related literature from Medline. Compared with the general population, metabolic syndrome is two to three times more common in SMDs. The evidence for this predates the era of antipsychotic drugs. Altered glucose metabolism and dyslipidemia seem to be integral to SMDs. However, major psychotropic drugs are associated with metabolic syndrome, because of their activity at the appetite-stimulating receptors. SMDs seem to trigger a pathogenic cycle that fuels metabolic syndrome. To explain these findings, a neural diathesis-stress model has been proposed. Furthermore, candidate genes associated with receptors for weight gain are implicated. Using metformin (≥750 mg/day) may significantly reduce metabolic risks, and the data support consideration of this intervention for psychiatric patients taking antipsychotics. The obstacles to the implementation of the available guidelines for monitoring metabolic effects and changing unhelpful lifestyles need to be overcome by making monitoring mandatory and integration of physical exercise into routine care. Drug development and genotyping for the risk factors are future solutions.
Similar articles
Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9.PMID: 19748369 French.
Metabolic syndrome and mental illness.
Newcomer JW.Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7.PMID: 18041878 Review.
Vergara-Rodriguez P, Vibhakar S, Watts J.Pharmacol Ther. 2009 Dec;124(3):269-78. doi: 10.1016/j.pharmthera.2009.07.004. Epub 2009 Jul 30.PMID: 19647020 Review.
Metabolic syndrome & psychiatric disorders.
Singh SM, Mattoo SK.Indian J Med Res. 2008 Sep;128(3):237-45.PMID: 19052333 Review.
Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
Yogaratnam J, Biswas N, Vadivel R, Jacob R.East Asian Arch Psychiatry. 2013 Mar;23(1):21-8.PMID: 23535629 Review.
Cited by
Singh VK, Muralidhar D, Malo PK, Bhaskarapillai B, Muralidharan K.Indian J Psychol Med. 2023 Jul;45(4):352-359. doi: 10.1177/02537176231155039. Epub 2023 Feb 25.PMID: 37483568 Free PMC article.
Och A, Och M, Nowak R, Podgórska D, Podgórski R.Molecules. 2022 Feb 17;27(4):1351. doi: 10.3390/molecules27041351.PMID: 35209140 Free PMC article. Review.
Snethen G, Brusilovskiy E, McCormick BP, Hiremath SV, Salzer MS.Ment Health Phys Act. 2021;20:10.1016/j.mhpa.2021.100381. doi: 10.1016/j.mhpa.2021.100381.PMID: 34745346 Free PMC article.
Coventry PA, Young B, Balogun-Katang A, Taylor J, Brown JVE, Kitchen C, Kellar I, Peckham E, Bellass S, Wright J, Alderson S, Lister J, Holt RIG, Doherty P, Carswell C, Hewitt C, Jacobs R, Osborn D, Boehnke J, Siddiqi N.Front Psychiatry. 2021 Aug 18;12:723962. doi: 10.3389/fpsyt.2021.723962. eCollection 2021.PMID: 34489764 Free PMC article.
Clinical Scenario of the Metabolic Syndrome.
Brede S, Serfling G, Klement J, Schmid SM, Lehnert H.Visc Med. 2016 Oct;32(5):336-341. doi: 10.1159/000449028. Epub 2016 Sep 19.PMID: 27921045 Free PMC article. Review.